David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3301
PUT
ConocoPhillips
COP
$158B
| $227K | ﹤0.01% |
3,400
-21,600
| -86% | -$1.45M |
|
3302
Gyre Therapeutics
GYRE
$708M
| $227K | ﹤0.01% |
3,733
+386
| +12% | +$24.8K |
|
|
NEWR
3303
CALL
DELISTED
New Relic, Inc.
NEWR
| $227K | ﹤0.01% |
2,300
-37,100
| -94% | -$3.67M |
|
3304
PUT
Atkore
ATKR
$3.16B
| $226K | ﹤0.01% |
10,500
| – | – |
|
|
DMC
3305
Del Monte Corp
DMC
$1.5B
| $226K | ﹤0.01% |
8,372
-938
| -10% | -$27.6K |
|
|
KREF
3306
KKR Real Estate Finance Trust
KREF
$489M
| $226K | ﹤0.01% |
11,278
-2,269
| -17% | -$45.9K |
|
|
CPL
3307
DELISTED
CPFL Energia S.A.
CPL
| $226K | ﹤0.01% |
14,552
| – | – |
|
3308
Universal Insurance Holdings
UVE
$1.2B
| $225K | ﹤0.01% |
7,263
-1,000
| -12% | -$35.9K |
|
3309
Tesla
TSLA
$1.38T
| $224K | ﹤0.01% |
12,000
-4,516,470
| -100% | -$90.7M |
|
|
SPLK
3310
DELISTED
Splunk Inc
SPLK
| $224K | ﹤0.01% |
1,800
-136,184
| -99% | -$17M |
|
|
SWI
3311
DELISTED
SolarWinds Corporation Common Stock
SWI
| $224K | ﹤0.01% |
+10,885
| New | +$204K |
|
3312
PUT
DaVita
DVA
$11.3B
| $223K | ﹤0.01% |
+4,100
| New | +$227K |
|
|
CBL
3313
DELISTED
CBL& Associates Properties, Inc.
CBL
| $223K | ﹤0.01% |
143,871
+34,582
| +32% | +$73.7K |
|
|
GRP.U
3314
DELISTED
Granite Real Estate Investment Trust
GRP.U
| $222K | ﹤0.01% |
+4,635
| New | +$211K |
|
|
RDUS
3315
DELISTED
Radius Recycling
RDUS
| $222K | ﹤0.01% |
9,263
-17,539
| -65% | -$415K |
|
3316
PUT
Tower Semiconductor
TSEM
$24B
| $222K | ﹤0.01% |
13,400
-3,100
| -19% | -$49.6K |
|
3317
Lennar Class A
LEN
$21.1B
| $221K | ﹤0.01% |
4,649
-77,141
| -94% | -$3.49M |
|
3318
VICI Properties
VICI
$28.9B
| $221K | ﹤0.01% |
+10,115
| New | +$214K |
|
|
CBD
3319
DELISTED
Companhia Brasileira de Distribuicao
CBD
| $221K | ﹤0.01% |
+9,478
| New | +$233K |
|
3320
NovaGold Resources
NG
$4.29B
| $220K | ﹤0.01% |
52,838
-310,568
| -85% | -$1.22M |
|
3321
CALL
National Healthcare
NHC
$3.52B
| $220K | ﹤0.01% |
+2,900
| New | +$230K |
|
3322
Trustmark
TRMK
$2.68B
| $220K | ﹤0.01% |
6,554
-4,319
| -40% | -$141K |
|
|
NBL
3323
DELISTED
Noble Energy, Inc.
NBL
| $220K | ﹤0.01% |
8,894
-33,446
| -79% | -$757K |
|
3324
Prospect Capital
PSEC
$1.2B
| $219K | ﹤0.01% |
33,642
-443,710
| -93% | -$2.95M |
|
3325
Tootsie Roll Industries
TR
$3.11B
| $219K | ﹤0.01% |
+7,223
| New | +$204K |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.